News

Article

Sponsored Content

Best Practices, Strategies & Use of Novel Biological Responses for Robust Cell-Based Potency Assays

Author(s):

Catalent

Cell-based assays (CBAs) are key tools for evaluating the potency of new biologic drugs. Catalent’s transcription-based bioassay simplifies and empowers the testing of new biologics.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Content
Site Logo
July 25th 2025

Executive Summary: End-To-End Regulatory CDMO Solutions: Development, Manufacturing, and Approval

Lonza
The road to market access is long and complex. Choosing a CDMO with experienced staff can prove vital to success. In this executive summary, Praveenkumar Devakadaksham and Dr. Roché Marcel Walliser explain all the ways they help make the journey from pharmaceutical development to commercial distribution as smooth as possible. Learn more about:
Site Logo
July 18th 2025

Executive Summary: Keys to Supplying Decentralized Trials: The Value of Direct-to-Patient Solutions and the Pharmacy-Led Model

Catalent
Site Logo
July 16th 2025

Innovations in Pregastric Absorption Drug Delivery & Orally Disintegrating Tablets

Catalent
Site Logo
July 15th 2025

Rethinking Inhalation Drug Development

Experic
What it takes to bring complex inhaled therapies to market—faster and smarter.
Site Logo
July 15th 2025

CDMO Solutions – Reducing Risk and Accelerating Time to Market

Experic
Discover how our precision processes and dedicated personal support can expedite even the most complex drug programs.
Site Logo
July 15th 2025

Unparalleled Expertise and Transparency Drive a Unique Development, Manufacturing, and Clinical Supply Experience

Experic